Treatments and outcomes according to important tobacco modalities
| Cigarette | Waterpipe | Oral tobacco | p Value | |
| N (%) | 3605 (46.9%) | 130 (1.7%) | 118 (1.5%) | |
| Inhospital therapy | ||||
| Glycoprotein IIb/III-a inhibitor | 339 (9.4%) | 10 (7.7%) | 1 (0.8%) | 0.005 |
| Thrombolytic therapy‡ | 1004 (57.9%) | 16 (29.6%) | 19 (24.4%)† | 0.001 |
| Aspirin | 3556 (98.6%) | 125 (96.2%) | 115 (97.5%) | 0.04 |
| Clopidogrel | 3042 (84.4%) | 115 (88.5%) | 104 (88.1%) | 0.25 |
| ACE inhibitor | 2538 (70.4%) | 106 (81.5%)* | 101 (85.6%)* | 0.001 |
| Angiotensin receptor blocker | 142 (3.9%) | 5 (3.8%) | 0 (0%) | 0.09 |
| β-Blockers | 2716 (75.3%) | 88 (67.7%) | 89 (75.4%) | 0.14 |
| Statins | 3458 (95.9%) | 124 (95.4%) | 114 (96.6%) | 0.88 |
| Calcium channel blockers | 188 (5.2%) | 3 (2.3%) | 6 (5.1%) | 0.34 |
| Discharge medications | ||||
| Aspirin | 3375 (95.5%) | 112 (88.2%)† | 112 (95.7%) | 0.001 |
| Clopidogrel | 2758 (76.7%) | 100 (76.9%) | 99 (83.9%) | 0.19 |
| β-Blockers | 2918 (81.1%) | 97 (74.6%) | 94 (79.7%) | 0.17 |
| ACE inhibitor | 2606 (72.5%) | 99 (76.2%)* | 104 (88.1%)* | 0.001 |
| Angiotensin receptor blocker | 204 (5.7%) | 10 (7.7%) | 2 (1.7%) | 0.11 |
| Statin | 3345 (93%) | 112 (86.2%)† | 109 (92.4%) | 0.01 |
| Calcium channel blockers | 205 (5.7%) | 4 (3.1%) | 5 (4.2%) | 0.36 |
| Inhospital complications | ||||
| Recurrent ischaemia | 508 (14.1%) | 35 (26.9%)* | 17 (14.4%) | 0.001 |
| Recurrent myocardial infarction | 53 (1.5%) | 3 (2.3%) | 1 (0.8%) | 0.63 |
| Ventilation | 144 (4.0%) | 13 (10%)* | 5 (4.2%) | 0.004 |
| Heart failure | 418 (11.6%) | 20 (15.4%) | 12 (10.2%) | 0.37 |
| Cardiogenic shock | 192 (5.3%) | 12 (9.2%) | 8 (6.8%) | 0.25 |
| Major bleeding | 16 (0.4%) | 3 (2.3%) | 1 (0.8%) | 0.07 |
| Stroke | 21 (0.6%) | 1 (0.8%) | 2 (1.7%) | 0.31 |
| Death | 121 (3.4%) | 11 (8.5%)* | 4 (3.4%) | 0.008 |
| 1-Month death | 205 (6.6%) | 14 (12.2%0 | 7 (7.2%) | 0.06 |
| 1-Year death | 274 (9.8%) | 15 (14.4%) | 11 (12.6%) | 0.22 |